Internet-delivered Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study
- Conditions
- Nonsuicidal Self-Injury
- Interventions
- Behavioral: Internet-delivered Emotion Regulation Individual Therapy for Adolescents
- Registration Number
- NCT02697019
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
The primary aim is to investigate the effectiveness of an Internet-delivered Emotion Regulation Individual Therapy for Adolescents (ERITA) with nonsuicidal self-injury (NSSI).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
A primary diagnosis of NSSI as defined in Section 3 in the fifth edition of the Diagnostic and Statistical Manual 5 of the American Psychiatric Association (DSM-5) < 1 NSSI episode during the past month At least one parent needs to commit to participate in the parent program
Bipolar disorder I or primary psychosis Severe suicidal ideation Ongoing substance dependence Insertion/withdrawal of psychopharmacological substances within two months prior to the treatment Other acute primary axis I diagnosis (e.g. anorexia nervosa) that demand treatment in first hand Current life circumstances that would hinder the treatment (i.e. ongoing domestic abuse) insufficient Swedish language skills Cocurrent treatment with Mentalization based therapy (MBT) or Dialectical behavioral therapy (DBT)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Internet-delivered ERITA Internet-delivered Emotion Regulation Individual Therapy for Adolescents -
- Primary Outcome Measures
Name Time Method Deliberate Self-Harm Inventory - 9 item version Baseline (30 days prior to treatment start), weekly (once a week following treatment start), post-treatment (12 weeks), and three and six months follow-up Change from baseline in self-harming behaviors when measures weekly, after 12 weeks, and at 3 and 6 months after treatment has ended
- Secondary Outcome Measures
Name Time Method Acceptance and Action Questionnaire (AAQ-7) Baseline (7 days prior to treatment start), post-treatment (12 weeks), three and six months follow-up] Change from baseline in acceptance and action after 12 weeks, at 3 and 6 months after treatment has ended
The Revised Child Anxiety and Depression Scale - Child and Parent rated (RCADS-C) Baseline (7 days prior to treatment start), post-treatment (12 weeks), three and six months follow-up] Change from baseline in anxiety and depression after 12 weeks, at 3 and 6 months after treatment has ended
Borderline Symptom List Behavior supplement (BSL-supplement) Baseline (30 days prior to treatment start), weekly (once a week following treatment start), post-treatment (12 weeks), and three and six months follow-up Change from baseline in self-destructive behaviors when measures weekly, after 12 weeks, and at 3 and 6 months after treatment has ended
Difficulties in Emotion Regulation Scale -16 item version (DERS-16) Baseline (30 days prior to treatment start), weekly (once a week following treatment start), post-treatment (12 weeks), and three and six months follow-up Change from baseline in difficulties in emotion regulation when measures weekly, after 12 weeks, and at 3 and 6 months after treatment has ended
Difficulties in Emotion Regulation Scale (DERS) Baseline (7 days prior to treatment start), post-treatment (12 weeks), three and six months follow-up] Change from baseline in difficulties in emotion regulation after 12 weeks, at 3 and 6 months after treatment has ended
Borderline personality features in childhood (BPFS-C) Baseline (7 days prior to treatment start), post-treatment (12 weeks), three and six months follow-up] Change from baseline in symptoms of borderline personality disorder after 12 weeks, at 3 and 6 months after treatment has ended
Suicidal Ideation Questionnaire (SIQ-JR) Baseline (7 days prior to treatment start), post-treatment (12 weeks), three and six months follow-up] Change from baseline in suicidal ideation after 12 weeks, at 3 and 6 months after treatment has ended
Trial Locations
- Locations (1)
Karolinska Institutet
🇸🇪Stockholm, Sweden